Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma

Study Status

Open to Enrollment

Study Description

This is a Phase I/II study of azacitidine in combination with R-CHOP chemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

Significant progress has been made in treatment of diffuse large B-cell lymphoma (DLBCL), but some patients are still not cured of their disease. Recently, researchers have begun to understand how reversible changes in expression of genes contribute to development of cancer and allow cancer cells to become resistant to the effects of chemotherapy. These reversible changes are termed "epigenetics" since they do not involve mutations in genes themselves. 

We are working to take advantage of the reversible nature of these changes by pre-treating patients with azacitidine, a drug which reverses epigenetic changes, before starting standard chemotherapy treatment. In this way, we hope to improve the sensitivity of lymphoma cells to chemotherapy.

Click here to visit our lymphoma blog.

Disease Status and/or Stage

Diffuse Large B-Cell Lymphoma (DLBCL)


Weill Cornell Medical College

Key Eligibility

  • Men and women age 18 and older
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Stage II (not appropriate for abbreviated chemoimmunotherapy and radiotherapy), III or IV disease
  • No previous treatment
  • Detailed eligibility discussed when you contact the study team

Principal Investigator

Rebecca Elstrom, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page